Balyasny Asset Management’s AC Immune ACIU Stock Holding History

Balyasny Asset Management’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25,841	Closed	-$82K	–	2725
2022 Q3	$82K	Buy	+25,841	New	+$81.4K	﹤0.01%	2418
2021 Q4	–	Sell	-733,180	Closed	-$4.92M	–	2173
2021 Q3	$4.92M	Buy	733,180 +472,324	+181%	+$3.38M	0.02%	828
2021 Q2	$2.07M	Buy	260,856 +234,798	+901%	+$1.62M	0.01%	996
2021 Q1	$198K	Buy	+26,058	New	+$186K	﹤0.01%	1583
2020 Q1	–	Sell	-33,653	Closed	-$287K	–	1112
2019 Q4	$287K	Buy	+33,653	New	+$224K	﹤0.01%	1067
2019 Q1	–	Sell	-110,000	Closed	-$1.04M	–	1369
2018 Q4	$1.04M	Sell	110,000 -437,054	-80%	-$4.13M	0.01%	890
2018 Q3	$4.38M	Buy	547,054 +520,953	+1,996%	+$5.24M	0.02%	748
2018 Q2	$243K	Buy	+26,101	New	+$258K	﹤0.01%	1580

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's ACIU Position: Q4 2022 in Review

Balyasny Asset Management sold out of AC Immune (ACIU) in Q4 2022, closing a stake of 25,841 shares — an estimated $82K sold.

Balyasny Asset Management first reported a position in ACIU in Q2 2018 and held it in 8 quarters. The position peaked at $4.92M in Q3 2021. 37 funds tracked by Wall St. Rank hold ACIU as of Q4 2022.

Balyasny Asset Management reported no remaining AC Immune position as of Q4 2022 after selling out during the quarter.
Balyasny Asset Management sold 25,841 AC Immune shares in Q4 2022, an estimated $82K.
Balyasny Asset Management first reported a position in AC Immune in Q2 2018 and held it in 8 quarters.
Balyasny Asset Management's AC Immune position peaked at $4.92M in Q3 2021.
37 funds tracked by Wall St. Rank held AC Immune as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.